Higher rates of triglyceride metabolism have recently been linked to increased all-cause, cardiovascular, cancer, and other mortality, but what does it mean for practising clinicians? Professor Børge G. Nordestgaard (University of Copenhagen, Denmark) discusses the new findings and their potential implications.
Are remnants more atherogenic than LDL? Novel genetic insights
Elias Björnson, University of Gothenburg, Sweden, discusses data from a UK Biobank Study which investigated the association between triglyceride-rich lipoproteins/remnant cholesterol and risk of coronary heart disease, and the atherogenicity of those particles compared to low-density lipoprotein particles.
Evinacumab in children with HoFH: What’s the evidence?
Dr Eliot Brinton discusses the unmet need for new treatments for children with homozygous familial hypercholesterolaemia (HoFH), and results of recent studies of evinacumab in children with HoFH aged 5-11 years and in those aged 12-17 years.
The SHASTA-2 trial: What the results mean for clinicians
Professor Daniel Gaudet, University of Montreal, Canada describes the results of the Phase 2b, SHASTA-2 dose-finding trial of plozasiran 10 mg, 25 mg or 50 mg s.c. or matched placebo in patients with severe hypertriglyceridaemia, and discusses what the findings mean for clinicians.
Growing evidence supports use of remnant cholesterol in ASCVD risk classification
Including elevated remnant cholesterol in risk assessment for atherosclerotic cardiovascular disease (ASCVD) may better indicate patients who are likely to have a CV event than current models, and help to guide future treatment strategies. Professor Børge G. Nordestgaard (University of Copenhagen, Denmark) discusses growing evidence supporting the use of remnant cholesterol measurement in both primary and secondary prevention settings.
Highlights of 2022 and looking forward to 2023
2022 was an important year for triglyceride-related research, with extensive clinical and preclinical data presented at international congresses and published in leading journals. When we asked Editorial Advisory Board members for their highlights, they agreed that the PROMINENT trial of triglyceride (TG) lowering to reduce cardiovascular (CV) risk, published in November 2022, was a major milestone.
